22 Apr 24
London, UK, 22 April 2024 – tranScrip Ltd, the leading specialist pharmaceutical consultancy who provide strategic expertise, therapeutic experience, and operational excellence across the entire product lifecycle, is pleased to announce the appointments of Dr Rienk Pypstra as Chief Medical Officer and Marianne Lambertson as Chief Commercial Officer. These appointments complete the Executive Leadership Team positioned to lead the talented group of scientific, regulatory, and commercial experts and drive long-term growth of the organisation.
“This will be a pivotal year for tranScrip as we strive to enable our clients to maximise the value of their innovative products for the benefit of patients worldwide. I am very pleased to have our full Leadership Team in place as we accelerate our efforts to build on our past success, identify new revenue opportunities, and use the experience of our world-class team members to deepen our relationships with clients.” said Mark Corbett, Chief Executive Officer. “Rienk brings a wealth of experience in clinical development as well as supporting commercialisation initiatives and his appointment speaks to the unique calibre of clinical expertise that tranScrip offers our clients. Marianne has extensive experience in global healthcare businesses and proven success in commercialisation across all stages of product development. I am confident that both will excel in their new roles and further enhance the quality and efficiency of our client services.”
Dr Pypstra is an established, medically qualified, drug development expert, having led numerous development programmes both in biotech and big pharma, through early and late-stage clinical development, to regulatory approvals, market access and successful commercialisation. His experience also spans the business side of pharma, with extensive experience in licensing and acquisition deals, including leading clinical due diligence for a number of assets. Over the past 7 years, Rienk has been VP Clinical Development for the Infectious Diseases (ID) Portfolio at Pfizer, where he started by integrating the AstraZeneca antibiotics portfolio, and subsequently drove various acquisitions and integrations in the ID space.
Ms Lambertson has a proven track record across a variety of therapeutic areas in Europe, Asia, and the Americas. Prior to joining tranScrip, Marianne was operating as an independent consultant for over 10 years, working with biotechnology businesses and pharmaceutical organisations on their commercial strategies across all lifecycle stages. Previously, Marianne held executive roles in pharmaceutical businesses, including Bayer, Altana Pharma, and Elan. She is an accomplished, driven leader with over 25 years of healthcare expertise, with recognized success in strategic and organisational planning, business development operations, communications, marketing, media, and fundraising.
tranScrip’s Executive Leadership team is completed by Mark Corbett, Chief Executive Officer, Gareth Dyson, Chief Financial Officer, Linda Summerton, Chief Scientific Officer, Karen Nugent, Chief Operating Officer, and Stacey Godfrey, Chief People Officer. For information on the full leadership team, please visit https://www.transcrip-group.com/about-us/our-leaders/
Our physicians, scientists and service experts can help to maximise the value of your products. Whatever your project requires, we have the people to meet your needs.
